Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.35 |
| ▸ | HRH2 | P25021 | 4/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891724 | 1.00 | CHRNB2 (0.38) | CHRNB2CHRNA4HRH3HRH2GRM5 | |
| SCHEMBL31247610 | 0.80 | CHRNB2 (0.39) | CHRNB2CHRNA4GRM5KLKB1MEN1 | |
| SCHEMBL14614714 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4GRM5KLKB1MEN1 | |
| SCHEMBL29364445 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4GRM5KLKB1MEN1 | |
| SCHEMBL14614599 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4GRM5KLKB1MEN1 | |
| SCHEMBL868299 | 0.79 | GRM5 (0.52) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL18795872 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4GRM5KLKB1MEN1 | |
| SCHEMBL19285183 | 0.78 | CHRNB2 (0.35) | CHRNB2CHRNA4GRM5KLKB1 | |
| SCHEMBL868367 | 0.78 | AKR1C3 (0.41) | CHRNB2CHRNA4GRM5KLKB1 | |
| SCHEMBL12891719 | 0.76 | DRD2 (0.40) | HRH3HRH2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | CHRNB2 78/4885CHRNA4 466/4885HRH3 3778/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | CHRNB2 2489/4885CHRNA4 1815/4885HRH3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.